Transformative Technologies for Experimental and Computational RNome Characterization and Functional Analysis

The Transformative Technologies for Experimental and Computational RNome Characterization and Functional Analysis opportunity is a forecasted funding initiative from the National Institutes of Health under the U.S. Department of Health and Human Services. It is part of the NIH Common Fund’s broader RNomics program, which is designed to advance the study of RNA biology by enabling comprehensive analysis of the full set of RNA molecules, referred to as the RNome, within cells and tissues. This initiative reflects NIH’s continued investment in foundational biomedical research infrastructure and cutting-edge technologies that can accelerate understanding of health and disease mechanisms. The primary objective of this funding opportunity is to support the development of transformative experimental and computational technologies that overcome current limitations in RNA research. The program emphasizes early-stage, high-risk, high-reward ideas that have not yet been validated at scale or within biologically relevant systems. The scope includes technologies that enable sequencing of RNA, detection of RNA modifications, analysis of RNA structure and interactions, and investigation of RNA function across different biological contexts, including cells and tissues. These efforts are expected to contribute to a more integrated and systems-level understanding of RNA biology. Funding will be provided through cooperative agreements, indicating substantial involvement from NIH program staff throughout the lifecycle of the project. The initiative is structured in phases. Phase 1 focuses on proof-of-concept and early validation of innovative technologies. Projects that successfully meet predefined milestones in Phase 1 may transition into Phase 2, where the emphasis shifts toward refinement, validation, and dissemination of tools for broader use by the scientific community. This phased approach ensures that only the most promising technologies advance to later stages of development and implementation. The program anticipates making approximately ten awards, with an estimated total program funding of eight million dollars and individual award ceilings of five hundred thousand dollars. No cost sharing or matching requirement is specified, which reduces financial barriers for applicants. Eligible applicants include a wide range of entity types such as nonprofit organizations, higher education institutions, government entities at various levels, tribal organizations, and for-profit entities including small businesses. The eligibility scope also extends to foreign institutions and other non-U.S. entities, reflecting the global relevance of RNA research. As this is a forecasted opportunity, applications are not yet being accepted. The notice is intended to provide advance awareness so that potential applicants can begin forming collaborations and developing competitive proposals. The estimated application due date is February 15, 2027, with an anticipated award date and project start date of December 1, 2027. The estimated posting date is October 1, 2026, which will mark the transition from forecast to active solicitation. The submission process will follow standard NIH application procedures once the Notice of Funding Opportunity is formally released. While specific application components are not yet detailed, applicants can expect to prepare comprehensive research proposals outlining their technological innovation, research plan, milestones, and anticipated impact. Evaluation criteria will likely emphasize innovation, feasibility, potential for transformative impact, and alignment with program goals. Applicants are encouraged to monitor updates and direct inquiries to the program contact via the provided email address.

Focus on high risk innovative RNA technology concepts and clearly define Phase 1 milestones for advancement to Phase 2